CHKB

Across TCGA pan-cancer cohorts, CHKB Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CHKB data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CHKB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHKB expression acts as an unfavorable survival marker.

LIHC and COAD are the cancer types where CHKB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.083	0.553	.009	12	view →
COAD	DFS	Median	All	0.235	0.699	.002	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CHKB–LIHC (DFS)

Open the LIHC breakdown →